PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) Spending and interest coverage
- R&D / revenue · 12 months: Value 119.11%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 53.30%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 119.11% | Research and development expense / revenue. Period ending 2026-06-30. $64.95M ÷ $54.53M × 100 ≈ 119.11% |
| Stock-based compensation / revenue · 12 months | 53.30% | Share-based compensation / revenue. Period ending 2026-06-30. $29.07M ÷ $54.53M × 100 ≈ 53.30% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 64.95M USD | Research and Development Expense |
| Revenue | 54.53M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 29.07M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -55.51M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $64.95M | $54.53M | $29.07M | $-55.51M | (m) | 119.11% | 53.30% | (m) | (m) |
| 2026-03-31 | $96.67M | $57.94M | $33.61M | $-119.02M | (m) | 166.84% | 58.00% | (m) | (m) |
| 2025-12-31 | $134.85M | $9.68M | $37.64M | $-214.64M | (m) | 1392.52% | 388.68% | (m) | (m) |
| 2025-09-30 | $170.44M | $11.79M | $41.09M | $-255.33M | (m) | 1446.11% | 348.60% | (m) | (m) |
| 2025-06-30 | $192.22M | $10.34M | $44.91M | $-281.61M | (m) | 1858.84% | 434.26% | (m) | (m) |
| 2025-03-31 | $209.22M | $137.94M | $44.53M | $-138.61M | (m) | 151.68% | 32.28% | (m) | (m) |
| 2024-12-31 | $222.52M | $135.16M | $45.96M | $-154.56M | (m) | 164.64% | 34.01% | (m) | (m) |
| 2024-09-30 | $234.24M | $133.35M | $46.52M | $-168.18M | (m) | 175.66% | 34.89% | (m) | (m) |
| 2024-06-30 | $241.43M | $217.25M | $46.45M | $-91.36M | (m) | 111.13% | 21.38% | (m) | (m) |
| 2024-03-31 | $239.93M | $89.25M | $44.51M | $-216.24M | (m) | 268.82% | 49.87% | (m) | (m) |
| 2023-12-31 | $220.57M | $91.37M | $40.91M | $-191.04M | (m) | 241.40% | 44.78% | (m) | (m) |
| 2023-09-30 | $195.55M | $140.98M | $37.27M | $-112.59M | (m) | 138.71% | 26.43% | (m) | (m) |
| 2023-06-30 | $177.50M | $57.63M | $34.29M | $-173.23M | (m) | 308.01% | 59.50% | (m) | (m) |
| 2023-03-31 | $153.06M | $54.92M | $32.45M | $-149.94M | (m) | 278.68% | 59.09% | (m) | (m) |
| 2022-12-31 | $135.56M | $53.91M | $31.32M | $-131.56M | (m) | 251.48% | 58.11% | (m) | (m) |
| 2022-09-30 | $120.75M | $5.15M | $30.78M | $-164.58M | (m) | 2342.82% | 597.13% | (m) | (m) |
| 2022-06-30 | $98.88M | $142.81M | $28.86M | $-5.02M | (m) | 69.24% | 20.21% | (m) | (m) |
| 2022-03-31 | $88.40M | $201.57M | $26.14M | $66.14M | (m) | 43.86% | 12.97% | (m) | (m) |
| 2021-12-31 | $82.28M | $200.58M | $24.66M | $71.97M | (m) | 41.02% | 12.29% | (m) | (m) |
| 2021-09-30 | $80.99M | $199.76M | $22.98M | $74.76M | (m) | 40.54% | 11.50% | (m) | (m) |
| 2021-06-30 | $84.60M | $60.75M | $22.51M | $-65.31M | (m) | 139.26% | 37.05% | (m) | (m) |
| 2021-03-31 | $80.78M | $872.00K | $22.65M | $-120.00M | (m) | 9263.76% | 2597.94% | (m) | (m) |
| 2020-12-31 | $74.88M | $853.00K | $22.01M | $-112.73M | (m) | 8778.90% | 2580.77% | (m) | (m) |
| 2020-09-30 | $69.59M | $749.00K | $22.09M | $-105.70M | (m) | 9291.72% | 2949.67% | (m) | (m) |
| 2020-06-30 | $60.48M | $797.00K | $22.33M | $-95.83M | (m) | 7587.95% | 2801.25% | (m) | (m) |
| 2020-03-31 | $52.79M | $769.00K | $22.92M | $-87.59M | (m) | 6864.50% | 2979.97% | (m) | (m) |
| 2019-12-31 | $50.84M | $814.00K | $23.59M | $-85.70M | (m) | 6245.21% | 2897.42% | (m) | (m) |
| 2019-09-30 | $51.88M | $752.00K | $22.54M | $-85.18M | (m) | 6898.27% | 2997.74% | (m) | (m) |
| 2019-06-30 | $57.90M | $802.00K | $23.77M | $-88.53M | (m) | 7219.95% | 2963.72% | (m) | (m) |
| 2019-03-31 | $79.77M | $914.00K | $26.31M | $-133.10M | (m) | 8727.90% | 2878.88% | (m) | (m) |
| 2018-12-31 | $101.18M | $955.00K | $27.01M | $-158.85M | (m) | 10595.08% | 2828.27% | (m) | (m) |
| 2018-09-30 | $118.17M | $990.00K | $30.17M | $-183.42M | (m) | 11936.87% | 3047.68% | (m) | (m) |
| 2018-06-30 | $140.97M | $954.00K | $30.23M | $-212.63M | (m) | 14777.25% | 3168.97% | (m) | (m) |
| 2018-03-31 | $143.56M | $27.49M | $28.06M | $-167.69M | (m) | 522.27% | 102.10% | (m) | (m) |
| 2017-12-31 | $134.55M | $27.52M | $26.76M | $-155.25M | (m) | 488.92% | 97.26% | (m) | (m) |
| 2017-09-30 | $140.89M | $27.46M | $24.57M | $-157.21M | (m) | 513.05% | 89.47% | (m) | (m) |
| 2017-06-30 | $126.41M | $27.53M | $28.91M | $-146.37M | (m) | 459.21% | 105.03% | (m) | (m) |
| 2017-03-31 | $124.74M | $1.05M | $26.81M | $-168.40M | (m) | 11891.23% | 2555.48% | (m) | (m) |
| 2016-12-31 | $119.53M | $1.05M | $24.93M | $-159.53M | (m) | 11330.24% | 2362.94% | (m) | (m) |
| 2016-09-30 | $97.58M | $1.19M | $23.00M | $-134.47M | (m) | 8193.12% | 1930.81% | (m) | (m) |
| 2016-06-30 | $87.93M | $1.33M | $14.56M | $-114.44M | (m) | 6591.23% | 1091.83% | (m) | (m) |
| 2016-03-31 | $68.36M | $1.28M | $12.44M | $-92.32M | (m) | 5344.72% | 972.24% | (m) | (m) |
| 2015-12-31 | $58.44M | $1.61M | $10.41M | $-79.94M | (m) | 3636.53% | 648.04% | (m) | (m) |
| 2015-09-30 | $50.66M | $3.31M | $8.53M | $-68.83M | (m) | 1529.01% | 257.59% | (m) | (m) |
| 2015-06-30 | $43.86M | $4.37M | $6.93M | $-59.30M | (m) | 1003.64% | 158.70% | (m) | (m) |
| 2015-03-31 | $39.68M | $19.21M | $5.96M | $-39.70M | (m) | 206.54% | 31.01% | (m) | (m) |
| 2014-12-31 | $38.45M | $50.85M | $5.60M | $-6.65M | (m) | 75.61% | 11.01% | (m) | (m) |
| 2014-09-30 | $33.95M | (m) | $5.29M | $-4.25M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $29.91M | (m) | $4.83M | $-680.00K | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $29.44M | (m) | $4.13M | $-13.44M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $26.05M | (m) | $3.13M | $-40.43M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $34.14M | (m) | $6.10M | $-41.41M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $24.17M | (m) | $2.97M | $-29.24M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |